INmune Bio raises $9.7M in registered direct offering of common stock and warrants

Inmune Bio, Inc.

Offering comprises 986,000 shares and warrants at $9.84 per unit; gross proceeds ~$9.7M.
Warrants have acceleration clause upon positive Phase 2 Alzheimer's top-line data (XPro1595).
Closing expected on or about April 29, 2024; Maxim Group LLC is sole placement agent.
Net proceeds to fund Phase 2 Alzheimer's trial (AD02) and Phase 1 mCRPC trial (INKmune).
Shares and warrants issued under effective shelf registration statement (S-3, No. 333-254221).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 986,000 shares of common stock and warrants at $9.84 per share, aggregate gross proceeds $9,702,240 (effective 2024-04-24).

Action: entry
Agreement: equity purchase
Counterparty: Purchasers
Value: 986,000 shares of common stock and warrants at $9.84 per share, aggregate gross proceeds $9,702,240
Effective: 2024-04-24

Exact text from the filing

On April 24, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser set forth on the signature page thereto (the “Purchasers) for the purchase and sale of an aggregate of 986,000 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 986,000 shares of its common stock (“Warrants”) in a registered direct offering.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Inmune Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at 6% cash fee of gross proceeds (effective 2024-04-24).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Value: 6% cash fee of gross proceeds
Effective: 2024-04-24

Exact text from the filing

Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 24, 2024, between the Company and Maxim Group LLC (the “Placement Agent”), the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.

View on SEC.gov

246 material agreements filed in the last 30 days. Browse all material agreements →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-036668

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.